IMMUNEO Therapeutics is dedicated to transforming the future of healthcare by pioneering innovative treatments for cancer and infectious diseases. Our focus on developing highly targeted and effective immunizations aims to set a new standard of care, working towards a future where cancer and serious infections no longer have to be life-altering conditions. Behind this mission is a team driven by expertise, innovation, and a shared vision.
Our goal is to create innovative, precise, and personalized immunotherapy solutions designed to address the unique needs of patients with unmet medical needs, as well as off-the-shelf solutions that are available to a large number of patients immediately. We are focused on tackling challenging diseases, including pancreatic cancer, advanced triple-negative breast cancer, and serious infectious diseases.
80%
Accuracy in IEDB* neoantigen validation
80%
Sensitivity in IEDB* neoantigen validation
30%
Increased immunogenicity through our peptide modifications
*The Immune Epitope Database was used as a validation dataset.